

2018 Primary Sclerosing Cholangitis Drug Development- Pipeline Analysis Report

https://marketpublishers.com/r/2F5568EAA1BEN.html

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2F5568EAA1BEN

Abstracts

Primary sclerosing cholangitis (PSC) is a chronic progressive GI disorder that affects the bile volume in the gall bladder. The slowly progressing condition causes inflammation and scaring of bile ducts, which results in improper flow of the digestive liquid.

Around 30 companies and universities are focusing on developing treatment options for Primary sclerosing cholangitis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Primary sclerosing cholangitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Primary sclerosing cholangitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Primary sclerosing cholangitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.



Contents

1 TABLE OF CONTENTS

- 1.1 List of Figures
- 1.2 List of Tables

2 PRIMARY SCLEROSING CHOLANGITIS PIPELINE ANALYSIS

- 2.1 Disease and Pipeline Overview
- 2.2 Primary Sclerosing Cholangitis Pipeline Snapshot
- 2.3 Primary Sclerosing Cholangitis Pipeline by Phase
- 2.4 Primary Sclerosing Cholangitis Pipeline by Company
- 2.5 Primary Sclerosing Cholangitis Pipeline by Mechanism of Action

3 PRIMARY SCLEROSING CHOLANGITIS- COMPANY WISE PIPELINE ANALYSIS

Acorda Therapeutics Inc

Albireo Pharma Inc

ChemomAb Ltd

Conatus Pharmaceuticals Inc

Dr. Falk Pharma GmbH

DURECT Corp

Gilead Sciences

HighTide Biopharmaceutical

Immune Pharmaceuticals Inc

Intercept Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Noxopharm Ltd

Orbsen Therapeutics Ltd

PharmAkea Therapeutics

Sancilio & Company Inc

Shire Plc

Tobira Therapeutics

4 PRIMARY SCLEROSING CHOLANGITIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name



Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN PRIMARY SCLEROSING CHOLANGITIS PIPELINE

6 APPENDIX

- 6.1 About VPA Research
- 6.2 Sources and Research Methodology



List Of Figures

LIST OF FIGURES

- Figure 1: Primary Sclerosing Cholangitis Pipeline by Phase, H1- 2018
- Figure 2: Primary Sclerosing Cholangitis Pipeline by Companies, H1- 2018
- Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
- Figure 4: Primary Sclerosing Cholangitis Pipeline by Mechanism of Action, H1- 2018
- Figure 5: Mechanism Wise Pipeline Drug Phases, H1-2018



List Of Tables

LIST OF TABLES

- Table 1: Primary Sclerosing Cholangitis Pipeline by Phase, H1- 2018
- Table 2: Primary Sclerosing Cholangitis Pipeline by Companies, H1- 2018
- Table 3: Primary Sclerosing Cholangitis Pipeline by Mechanism of Action, H1- 2018
- Table 4: Acorda Therapeutics Inc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 5: Albireo Pharma Inc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 6: ChemomAb Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 7: Conatus Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 8: Dr. Falk Pharma GmbH Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 9: DURECT Corp Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 10: Gilead Sciences Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 11: HighTide Biopharmaceutical Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 12: Immune Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 13: Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 14: NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 15: Noxopharm Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 16: Orbsen Therapeutics Ltd Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 17: PharmAkea Therapeutics Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 18: Sancilio & Company Inc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 19: Shire Plc Primary Sclerosing Cholangitis Pipeline, May 2018
- Table 20: Tobira Therapeutics Primary Sclerosing Cholangitis Pipeline, May 2018



I would like to order

Product name: 2018 Primary Sclerosing Cholangitis Drug Development- Pipeline Analysis Report

Product link: https://marketpublishers.com/r/2F5568EAA1BEN.html

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2F5568EAA1BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

:
:
:
:
:
:
:
:
:
**All fields are required
Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970